A citation-based method for searching scientific literature

Yamin Shu, Yufeng Ding, Yanxin Liu, Pan Wu, Xucheng He, Qilin Zhang. Front Pharmacol 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment.
Sinead A Noonan, Peter B Sachs, D Ross Camidge. J Thorac Oncol 2016
27
100

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
Colin F Spraggs, Laura R Budde, Linda P Briley, Nan Bing, Charles J Cox, Karen S King, John C Whittaker, Vincent E Mooser, Alaknanda J Preston, Steven H Stein,[...]. J Clin Oncol 2011
199
100

Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody.
Nobuaki Mamesaya, Hirotsugu Kenmotsu, Mineo Katsumata, Takashi Nakajima, Masahiro Endo, Toshiaki Takahashi. Invest New Drugs 2017
35
100


Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib.
Andrew J Piper-Vallillo, Daniel B Costa, Marwa A Sabe, Aarti Asnani. JACC CardioOncol 2020
5
100

Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism.
Takamasa Hotta, Yukari Tsubata, Kosuke Hamai, Akari Tanino, Misato Kobayashi, Atsushi Nakamura, Jun Sugisaka, Masafumi Hongoh, Noriyuki Ishihara, Nobuhisa Ishikawa,[...]. Respir Investig 2021
3
100


Rare mutations in non-small-cell lung cancer.
Manolo D'Arcangelo, Armida D'Incecco, Federico Cappuzzo. Future Oncol 2013
15
100

Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer.
Yoshiya Matsumoto, Tomoya Kawaguchi, Norio Yamamoto, Kenji Sawa, Naoki Yoshimoto, Tomohiro Suzumura, Tetsuya Watanabe, Shigeki Mitsuoka, Kazuhisa Asai, Tatsuo Kimura,[...]. Intern Med 2017
8
100

Cardiovascular toxicity of PI3Kα inhibitors.
Chandu Sadasivan, Pavel Zhabyeyev, Dina Labib, James A White, D Ian Paterson, Gavin Y Oudit. Clin Sci (Lond) 2020
7
100

Metastatic sites and survival in lung cancer.
M Riihimäki, A Hemminki, M Fallah, H Thomsen, K Sundquist, J Sundquist, K Hemminki. Lung Cancer 2014
387
100

Management of colonic volvulus.
Daniel Gingold, Zuri Murrell. Clin Colon Rectal Surg 2012
57
100

DNA Repair Gene Polymorphisms in Relation to Non-Small Cell Lung Cancer Survival.
Yuliang Su, Huan Zhang, Fangxiu Xu, Jinyu Kong, Herbert Yu, Biyun Qian. Cell Physiol Biochem 2015
14
100

Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.
Richard J Pietras, Diana C Márquez, Hsiao-Wang Chen, Eugene Tsai, Olga Weinberg, Michael Fishbein. Steroids 2005
163
100

Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.
Gary H Lyman, Kari Bohlke, Alok A Khorana, Nicole M Kuderer, Agnes Y Lee, Juan Ignacio Arcelus, Edward P Balaban, Jeffrey M Clarke, Christopher R Flowers, Charles W Francis,[...]. J Clin Oncol 2015
533
100

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
Tohru Ohmori, Toshimitsu Yamaoka, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryou Manabe, Hironori Sagara. Int J Mol Sci 2021
14
100

9
100

Interstitial lung disease associated with drug therapy.
P Camus, S Kudoh, M Ebina. Br J Cancer 2004
125
100

Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab.
K Knobloch, J Tepe, R Lichtinghagen, H J Luck, P M Vogt. Int J Cardiol 2008
15
100

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).
Hiromi Watanabe, Eiki Ichihara, Hirohisa Kano, Kiichiro Ninomiya, Mitsune Tanimoto, Katsuyuki Kiura. Intern Med 2017
20
100

Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity.
Christian Cadeddu Dessalvi, Martino Deidda, Antonio Noto, Clelia Madeddu, Lucia Cugusi, Ciro Santoro, Teresa López-Fernández, Maurizio Galderisi, Giuseppe Mercuro. Antioxid Redox Signal 2021
6
100


Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Xiaohua Gu, Qiang Zhang, Yun-Bo Chu, Yi-Yang Zhao, Yan-Jun Zhang, David Kuo, Betty Su, Bin Wu. Lung Cancer 2019
34
100

Cardiovascular toxic effects of targeted cancer therapy.
Kazuko Tajiri, Kazutaka Aonuma, Ikuo Sekine. Jpn J Clin Oncol 2017
10
100

Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report.
Ryosuke Hirabayashi, Daichi Fujimoto, Yukari Satsuma, Masaki Hirabatake, Keisuke Tomii. Invest New Drugs 2018
10
100


Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
Woon Chien Teng, Jing Wen Oh, Lee Sun New, Michelle D Wahlin, Sidney D Nelson, Han Kiat Ho, Eric Chun Yong Chan. Mol Pharmacol 2010
81
100

Twenty years of anti-HER2 therapy-associated cardiotoxicity.
Noam F Pondé, Matteo Lambertini, Evandro de Azambuja. ESMO Open 2016
55
100

Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).
Kartik Anand, Joe Ensor, Barry Trachtenberg, Eric H Bernicker. JACC CardioOncol 2019
24
100

Missense mutations of the BRAF gene in human lung adenocarcinoma.
Katsuhiko Naoki, Tzu-Hsiu Chen, William G Richards, David J Sugarbaker, Matthew Meyerson. Cancer Res 2002
235
100

BRAF and RAS mutations in human lung cancer and melanoma.
Marcia S Brose, Patricia Volpe, Michael Feldman, Madhu Kumar, Irum Rishi, Renee Gerrero, Eugene Einhorn, Meenhard Herlyn, John Minna, Andrew Nicholson,[...]. Cancer Res 2002
843
100

Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.
Wei-Xiang Qi, Da-Liu Min, Zan Shen, Yuan-Jue Sun, Feng Lin, Li-Na Tang, Ai-Na He, Yang Yao. Int J Cancer 2013
68
100

Histopathological Features of Drug-Induced Liver Injury Secondary to Osimertinib.
Iván González, Deyali Chatterjee. ACG Case Rep J 2019
5
100

Considerations for second-line therapy of non-small cell lung cancer.
Thomas E Stinchcombe, Mark A Socinski. Oncologist 2008
91
100

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer.
Tejas Patil, Jose M Pacheco, Anastasios Dimou, William T Purcell, Candice Rossi, Paul A Bunn, Robert C Doebele, D Ross Camidge, Lisa Ferrigno. Front Oncol 2020
1
100

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
962
100

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Glenwood Goss, Chun-Ming Tsai, Frances A Shepherd, Lyudmila Bazhenova, Jong Seok Lee, Gee-Chen Chang, Lucio Crino, Miyako Satouchi, Quincy Chu, Toyoaki Hida,[...]. Lancet Oncol 2016
425
100

Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma.
Ekaterina Pisareva, Nadezhda Gutkina, Sergei Kovalenko, Sarah Kuehnapfel, Arndt Hartmann, Lucie Heinzerling, Regine Schneider-Stock, Lyudmila Lyubchenko, Vladimir A Shamanin. Melanoma Res 2014
3
100



Molecular footprints of human lung cancer progression.
Jun Yokota, Takashi Kohno. Cancer Sci 2004
97
100

Osimertinib-induced severe interstitial lung disease: A case report.
Mengdi Fan, Ting Mo, Lulei Shen, Li Yang. Thorac Cancer 2019
4
100

Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician.
Irving E Perez, Sara Taveras Alam, Gabriel A Hernandez, Rhea Sancassani. Clin Med Insights Cardiol 2019
56
100

EGFR Inhibitor Gefitinib Induces Cardiotoxicity through the Modulation of Cardiac PTEN/Akt/FoxO3a Pathway and Reactive Metabolites Formation: In Vivo and in Vitro Rat Studies.
Ali Alhoshani, Fawaz E Alanazi, Moureq R Alotaibi, Mohamed W Attwa, Adnan A Kadi, Abdullah Aldhfyan, Sabah Akhtar, Shireen Hourani, Abdelali Agouni, Asad Zeidan,[...]. Chem Res Toxicol 2020
10
100

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.